Introduction
Over the last few years, high-dose chemo-or chemoradiotherapy with autologous hematopoietic progenitor cell support has been increasingly used for the treatment of various malignancies. 1 Patients with high-risk multiple myeloma (MM) seem to benefit particularly from this type of treatment. [2] [3] [4] [5] Moreover, in patients under the age of 65 with aggressive MM, the results of a recent randomized trial of the Intergroupe Francais du Myelome have shown the superiority of autologous transplantation over conventional treatment. 6 During the past few years, peripheral blood progenitor cells (PBPC) have progressively replaced bone marrow (BM) cells as the source of stem cells to rescue hematopoiesis after myeloablative treatment. One of the most important advantages of PBPC is to shorten the duration of marrow aplasia, which could make this technique safer. 7 This is especially interesting in elderly patients, as the median age of MM patients is generally higher than in other diseases usually treated with intensive treatments.
It has previously been reported that increased numbers of PBPC can be collected by leukaphereses during the marrow recovery phase following intensive non-myeloablative chemotherapy. 8 Studies in dogs and humans have shown that PBPC recirculation is usually observed after high-dose cyclophosphamide (HDCYC)-induced marrow aplasia. 9, 10 Furthermore, it has been demonstrated that hematopoietic support is not necessary after HDCYC. 11 As HDCYC has been reported to be efficient in the treatment of refractory MM, 12 we have used it at the dose of 7 g/m 2 , either alone or followed by hematopoietic growth factors (HGF), for PBPC mobilization in 116 patients planned to receive subsequently autologous PBPC transplantation (ABPCT).
The aims of this monocentric study were: (1) to evaluate in MM patients the ability of HDCYC to mobilize circulating hematopoietic progenitors and to determine the parameters associated with successful mobilization; and (2) to analyze the predictive factors for hematologic recovery following reinfusion of PBPC after myeloablative treatment in a group of MM patients mobilized with HDCYC.
Patients and methods

Patients
MM was defined by the diagnostic criteria of the South West Oncology Group of USA. 13 All the patients had aggressive MM defined as: (1) stage II or III MM at diagnosis according to the Durie-Salmon staging; 14 (2) plasmocytoma or stage I MM with no response to treatment or relapse after a previous response to treatment; and (3) plasma cell leukemia. The patients were eligible for HDCYC if they had aggressive MM, no history of cyclophosphamide-induced cystitis, plasma creatinine levels of less than 150 mol/l and normal hepatic and cardiac function. All received HDCYC treatment as both debulking and mobilizing treatment and were potential candidates for high-dose chemo-or chemoradio-therapy. The patients were advised of the procedures and attendant risks and gave written informed consent prior to entry into the treatment program. The protocol was approved by the Comité des Essais Cliniques at the University Hospital of Bordeaux.
Patient characteristics are summarized in Table 1 . One hundred and sixteen patients (male 74, female 42) with a median age of 56 years (range 32-67) were evaluated. At diagnosis, 79 patients had stage III MM or plasma cell leukemia, while 13 had stage II MM, 24 had stage I MM or plasmocytoma. The isotype of the monoclonal component was IgG in 81 cases, IgA in 19, IgM in two and only Bence-Jones protein in 13. Only one patient had non-secretory MM. Beta2-microglobulin levels at diagnosis were known for only 66 patients and ranged from 1.3 to 13.5 mg/l (median 2.8). The median time between diagnosis and HDCYC was 7 months (range 1-207). Before HDCYC all patients had previously received one or several lines of standard chemotherapy for less than 1 year (n = 85), between 1 and 2 years (n = 14) or for more than 24 months (n = 17); 72 patients had received only one line of chemotherapy (association of vincristine, doxorubicin and high-dose steroids (VAD or VAMP regimens) 15, 16 in 62 cases or alkylating agent-containing regimen in 10 other cases) while the other 44 patients were treated with at least two different lines of chemotherapy (including in all cases chemotherapy regimens with alkylating agent and high-dose steroids). Thus, a total of 54 patients had received alkylating agent-containing regimens and 106 chemotherapy with high-dose steroids. None of the patients had previously received high-dose chemotherapy and only one had been treated with interferon-alpha. At the time of starting HDCYC, 48 patients were considered as non-responsive to the ongoing chemotherapy, as the decrease in the M-component was less than 50% of the initial value.
HDCYC treatment
All the patients received cyclophosphamide (CYC) (Endoxan; Asta Medica, Merignac, France) administered at the dose of 7 g/m 2 in four separate 1-h infusions every hour as previously described. 17 For urothelial protection, all patients were given 2-mercapto-ethan sulfonate (Uromitexan; Asta Medica) starting 1 h before HDCYC treatment and given 36 h following the end of this treatment. Hyperhydration (3 l/m 2 day) was given over 48 h starting 12 h before the first CYC dose associated with urine alkalinisation.
After HDCYC, 42 of the patients did not receive HGF (control group), while 74 other patients (HGF group) received either recombinant E. coli, non-glycosylated human granulocytemacrophage colony-stimulating factor (GM-CSF) (Sandoz (RueilMalmaison, France)/Schering-Plough (Levallois-Perret, France)) (5 g/kg/day) (n = 55) or E. coli, non-glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) (Amgen (Paris, France)/Produits Roche (Neuilly Sur Seine, France)) (5 g/kg/day) (n = 19). The only significant differences observed between the patient characteristics of the control and the HGF groups consisted of the proportion of stage III at diagnosis, which was higher in the control group (35/42 (control group) vs 44/74 (HGF group); P = 0.015). In all cases HGF was started 24 h after HDCYC and continued until completion of leukaphereses.
All patients received sterile food and gut decontamination with non-absorbable antibiotics starting the day before administration of HDCYC; when the neutrophil count was less than 0.5 × 10 9 /l, broad-spectrum intravenous (i.v.) antibiotics were started at the onset of fever (38.5°C) and continued until remission of fever and neutropenia. Amphotericin B was added in case of documented fungal infection or persistent fever despite antibiotic administration.
White blood and platelet counts were measured daily following HDCYC therapy. Irradiated prophylactic single donor platelet and packed red blood cell (RBC) transfusions were administered when the platelet count was less than 20 or 30 × 10 9 /l and the hemoglobin level less than 8 g/dl, respectively. No prophylactic or therapeutic granulocyte transfusions were administered.
PBPC collection, cryopreservation and stem cell assays
Aphereses were planned during the recovery phase following HDCYC-induced aplasia and started when the leukocyte and platelet counts showed a spontaneous rise and reached 1 × 10 9 /l and 70 × 10 9 /l, respectively. The procedure was performed according to previously described techniques. 18 Ten liters of blood were processed at each apheresis on a Fenwall CS-3000 continuous flow cell separator at a flow rate of 60 ml/min (Fenwall Division, Baxter Healthcare, Round Lake, IL, USA). Six leukaphereses were systematically planned, while more recently in one case, the number of leukaphereses was dependent on the number of CD34 + cells collected (at least 2 × 10 6 /kg). After completion of leukaphereses, bone marrow (BM) was harvested in most cases under general anesthesia as a precautionary measure (at least 2 × 10 8 mononuclear cells (MNC)/kg). PBPC and BM cells were depleted of red blood cells and plasma by centrifugation and subsequently cryopreserved using standard techniques in 10% dimethyl sulfoxide. 18 Granulocyte-macrophage colony-forming unit (CFU-GM) assays and CD34 + cell evaluation (for 90 patients) were performed on leukapheresis products. For CFU-GM assay after Ficoll-Hypaque gradient separation, 10 5 /ml cells were plated in triplicate on 35-mm Falcon-Petri dishes using semi-solid medium containing 0.3% agar (Difco, Detroit,MI, USA), 12% fetal calf serum (Institut Jacques Boy, Reims, France), 10% human placenta-conditioned medium and MacCoy's 5A medium (Gibco-BRL, Cergy-Pontoise, France). After 14 days of incubation at 37°C in a fully humidified 5% CO 2 atmosphere, colonies of CFU-GM cells were evaluated and scored following standard methods. 19 For CD34 analysis, the cells were incubated for 30 min at 4°C with fluorescein isothiocyanate-conjugated monoclonal antibody (anti-CD34) (Immunotech, Marseille, France). After incubation cell populations were analyzed by flow cytometry as previously described. 17 
Autologous PBPC transplantation: conditioning regimen and supportive therapy
After HDCYC and leukaphereses, patients were planned to receive a combination of high-dose melphalan (HDM) (140 mg/m 2 ) and total body irradiation (TBI) (8-13.5 Gy) or for previously irradiated patients, busulfan (4 mg/kg/day on 4 consecutive days). Reinfusion of PBPC (with or without BM) was performed on a single day, 24 h after the last dose of radiotherapy or chemotherapy. During the aplastic phase the patients were isolated in positive airway pressure rooms. Supportive care conditions were identical to those after HDCYC.
Statistical analysis
Time to hematological recovery was defined by the day after HDCYC or ABPCT on which patients achieved 0.5 × 10 9 neutrophils/l or 50 × 10 9 platelets/l without transfusions, and was estimated using the Kaplan-Meier product limit method. 20 The threshold values of total CFU-GM and CD34
+ cells necessary to support complete hematopoietic reconstitution were determined according to estimates in the literature. The criteria for poor PBPC collection were less than 25 × 10 4 /kg CFU-GM cells 21 or 2 × 10 6 /kg CD34 + cells. 22 Comparisons between the duration of hospitalization, antibiotic administration, the numbers of CFU-GM or CD34 + cells harvested, and the numbers of RBC or platelet transfusions administered were performed using the Wilcoxon test. For patients transplanted with PBPC alone, the number of CFU-GM and CD34
+ cells infused was divided into Ͻ 25 or у 25 × 10 4 /kg and Ͻ 2 or у 2 × 10 6 /kg, respectively. The comparison between groups was made using the log-rank test. Multivariate logistic regression was used to assess factors associated with PBPC collection and kinetics of engraftment. In the multivariate analysis, only variables significant at the level of 0.15 in the univariate analysis were considered. If colinearity was observed, the final model was obtained by using a forward procedure. 23 
Results
Hematopoietic recovery and supportive care after HDCYC
After HDCYC, the median number of days to achieve more than 0.5 × 10 9 granulocytes/l and more than 50 × 10 9 platelets/l was 15 (range 8-48) and 15 days (range 0-86), respectively. Twenty-nine patients never received platelet transfusions while only six patients did not receive RBC transfusions. A median number of 4.5 packed RBC (range 0-15) and one platelet unit (range 0-12) was transfused per patient. The number of days of hospitalization after HDCYC ranged from 13 to 55 (median 22.5).
During marrow aplasia, 110 patients exhibited fever (control group 38/42; HGF group 72/74). The median duration of i.v. antibiotics was 10.5 days (range 0-38). Twenty-one of the 110 febrile patients received amphotericin B treatment in addition. Three patients died after HDCYC, two from septic shock, occurring for one during the aplastic phase and for the other after the first leukapheresis. Another patient died just before the first leukapheresis from cardiac arrest possibly due to septic shock. These three patients had received HGF (GM-CSF 1; G-CSF 2).
The impact of different variables on hematologic toxicity after HDCYC was tested (age, sex, DS stage, type of gammopathy, beta2-microgobulin level, number of lines of treatment, previous alkylating agent-containing regimen, duration of chemotherapy, interval diagnosis-HDCYC, response before HDCYC, use of HGF).
Transfusion requirements and the median number of days of i.v. antibiotics were not different in the HGF group and the control group, while the median number of days of hospitalization was significantly decreased in the HGF group (control group 24, range 17-46; HGF group 22, range 13-55) (P = 0.05). HGF dramatically decreased the median number of days to reach 0.5 × 10 9 neutrophils (control group 17, range 8-30; HGF group 14, range 10-48) (P = 0.0004) but not the recovery of more than 50 × 10 9 platelets/l after HDCYC (control group, median day 14.5, range 0-43; HGF group, median day 15, range 0-86) (P = 0.88) (Figure 1) . Out of the other variables tested, previous chemotherapy regimen with alkylating agent, more than 1 year of prior therapy, and more than one line of treatment before HDCYC were in a univariate analysis found to be important adverse factors for both transfusion requirement (P Ͻ 0.002), duration of administration of i.v. antibiotics and hospitalization (P Ͻ 0.05), and neutrophil or platelet recovery after HDCYC (P Ͻ 0.001). More than a 1 year interval between diagnosis and HDCYC also had a significant impact on these parameters (P Ͻ 0.02) except on the number of days of hospitalization. Responders to treatment before HDCYC seemed to have a significantly lower RBC requirement (P Ͻ 0.012). Multivariate analysis was not possible because of colinearity among the variables.
PBPC mobilization and collection
For 10 patients, PBPC collection could not be undertaken for different reasons: death from septic shock (n = 2) or cardiac arrest (n = 1), bacteremia at time of leukaphereses (n = 2), vascular access problem (n = 2), myocardiopathy (n = 1), persistent low blood counts (n = 1), and cholestasis (n = 1).
For the remaining 106 patients, a median number of six leukaphereses (range 2-7) was performed. Leukaphereses began between day 7 and day 36 (median 17) following HDCYC. The median day post-HDCYC of first leukapheresis was significantly earlier in the HGF group (16 range 7-36) than in the control group (19, range 13-34) (P Ͻ 0.00001). The median numbers of MNC, CFU-GM and CD34
+ cells collected per patient were of 6.3 × 10 8 /kg (range 0.01-378), 6.9 × 10 4 /kg (range 0.01-578) and 6.8 × 10 6 /kg (range 0.4-160), respectively. Table 2 shows the results of the univariate analysis testing the influence of different patient characteristics on the median number of CFU-GM and CD34
+ cells collected. Patients who received HDCYC without HGF had fewer CFU-GM and CD34
+ cells collected than patients who received HDCYC followed by G-CSF or GM-CSF. The difference was statistically significant for CFU-GM cells (P = 0.01) but not for CD34 + cells. Among the other parameters, more than 14 days to achieve an unsubstituted platelet count of 50 × 10 9 /l after HDCYC, more than 1 year interval between diagnosis and HDCYC, prior chemotherapy for more than 1 year, and more than one line of treatment before HDCYC were associated with a lower number of both CFU-GM and CD34 Kaplan-Meier probability of achieving 0.5 × 10 9 neutrophils/l (a) and 50 × 10 9 platelets/l (b) after high-dose cyclophosphamide (HDCYC) in patients receiving hematopoietic growth factors (HGF group) and those not receiving HGF (control group).
HDCYC and the use of HGF after HDCYC were favorable factors associated with collection of more than 25 × 10 4 CFU-GM cells/kg. More than a 1 year interval between diagnosis and HDCYC was identified as the only adverse factor for collection of more than 2 × 10 6 CD34 + cells/kg. Multivariate logistic regression (Table 3) showed that the most important factors associated with poor PBPC collection were the absence of HGF post-HDCYC and a previous chemotherapy regimen containing an alkylating agent for the number of CFU-GM cells (P Ͻ 0.005) and no response to conventional chemotherapy, more than 1 year interval between diagnosis and HDCYC, and the absence of HGF for the number of CD34 + cells (P Ͻ 0.03). Although this was a sequential study, when the year of HDCYC administration was included as a cofactor in the multivariate logistic regression analysis its results were not modified (P = 0.441 and P = 0.769 for the collection of more than 25 × 10 4 CFU-GM cells/kg and 2 × 10 6 CD34 + cells/kg, respectively). (control group 6/42; HGF group 13/74). Three pulmonary complications were observed, all in the HGF group, one pneumonia related to herpes infection and two non-documented pneumonia occurring during the neutropenic period.
Extrahematologic toxicity after HDCYC
Hematopoietic recovery after ABPCT
Among the 106 patients collected, six did not undergo autologous PBPC transplantation (ABPCT): five of them received an allogeneic bone marrow transplantation while one patient failed to obtain an adequate collection of either PBPC or BM cells for an autograft. All the remaining 100 patients underwent subsequent autotransplant with PBPC either alone (n = 83) or associated with back-up BM cells (n = 17) when the CFU-GM content of leukapheresis was low (less than 2 × 10 4 /kg). Before ABPCT, the preparatory regimen for 96 patients consisted of a combination of HDM (140 mg/m 2 ) and TBI (8-13.5 Gy). Prior to HDM/TBI, three of the latter patients received cyclophosphamide (60 mg/kg/day on 2 consecutive days). Another two patients, in whom the total number of hematopoietic progenitors contained in the combined leukaphereses and BM products was low (less than 1. Hematological reconstitution after peripheral blood progenitor cell (PBPC) supported high-dose therapy. The analysis is based on the 75 patients autografted with PBPC alone without prophylactic HGF post-graft and after a conditioning regimen consisting of HDM-TBI.
Influence of the number of CFU-GM and CD34
+ cells infused on the Kaplan-Meier probability of reaching more than 0.5 × 10 9 neutrophils/l (a and b) and 50 × 10 9 platelets/l (c and d) after autografting is indicated.
(n = 2) which was started on day +1 post-graft and continued until the absolute neutrophil count reached 1 × 10 9 /l for 3 consecutive days.
For the 83 patients grafted with PBPC alone, the median number of days to reach 0.5 × 10 9 neutrophils/l and 50 × 10 9 platelets/l was 13 (range 0-93) and 13 (range 0-440), respectively. In this group of patients, one patient died of acute cardiac failure after reinfusion of PBPC and was not evaluable. Of the 82 remaining patients, hematopoietic reconstitution post-ABPCT was rapid and complete in 78. Four patients had to receive either curative treatment with HGF (n = 1) or reinfusion of back-up BM cells (n = 1) or both (n = 2). Of these four patients, all had poor PBPC mobilization as the number of CFU-GM cells and CD34 + cells was less than 25 × 10 4 /kg (n = 4) and 2 × 10 6 /kg (n = 2), respectively. In order to avoid any bias in the analysis we excluded from the group of 83 patients grafted with PBPC alone eight patients who received either a conditioning regimen different than HDM-TBI or prophylactic HGF post-graft. Figure 2 shows the relationship between the number of CFU-GM and CD34
+ cells infused and hematological recovery kinetics for these 75 patients. The rates of neutrophil and platelet recovery were found to be influenced significantly by the number of CFU-GM cells (P Ͻ 0.0001), but not by the number of CD34 + cells infused. Table 4 shows the results observed in univariate analysis testing the other factors associated with hematopoietic recovery after ABPCT for this subgroup of patients. Fewer than 14 days to achieve an unsubstituted platelet count of 50 × 10 9 /l after HDCYC, only one line of treatment before HDCYC, response to conventional chemotherapy prior HDCYC and the absence of alkylating agent in previous chemotherapy regimens were all associated with more rapid platelet (P Ͻ 0.05) but not granulocyte recovery after ABPCT. None of the other factors significantly influenced either granulocyte or platelet recovery post-transplant. Multivariate Cox analysis was not possible because of colinearity. However, for patients who received more than 1 year of prior chemotherapy, and who needed fewer than 14 days after HDCYC to achieve an unsubstituted platelet count of 50 × 10 9 /l, there was a quicker platelet recovery post-ABPCT. 
Discussion
In this monocentric study, we investigated whether or not a single dose of HDCYC of 7 g/m 2 either alone or with HGF would allow sufficient PBPC to be collected during recovery for successful autotransplant in MM patients. To our knowledge this is the largest series reported of MM patients treated with this dose and who subsequently underwent ABPCT.
The rate of hematopoietic recovery observed in our study after ABPCT was quite similar to that observed after ABPCT in other studies 5, 24 and better than that observed after ABMT. 3, 4 Thus, a more rapid neutrophil and platelet engraftment remains the main advantage of PBPC transplantation over BM as hematopoietic support after high-dose chemo-or chemoradio-therapy in MM (as well as in other hematological malignancies). 25 As previously observed in our earlier experience with autografting, our results demonstrate a strong influence of the number of CFU-GM cells infused on the rate of hematopoietic recovery and confirm that a CFU-GM dose of 25 × 10 4 /kg is required for rapid and complete hematopoietic recovery. 7, 21 The minimum number of CD34 + cells required for successful engraftment is unknown but is probably around 2-3 × 10 6
CD34
+ cells/kg. One study suggested that in MM patients a level of 2 × 10 6 /kg is clinically useful for neutrophil recovery but may not be sufficient for rapid platelet recovery, particularly if the patients have received more than 2 years of chemotherapy. 24 We cannot confirm this assertion, probably because the number of patients who received less than 2 × 10 6
+ cells/kg was too low in our study. Concerning the other parameters tested, our results confirm that prompt recovery after HDCYC (Ͻ 14 days) is strongly associated with platelet recovery after ABPCT, particularly for patients who have received more than 1 year of chemotherapy. 22, 24 The optimal chemotherapy regimen for mobilizing PBPC has not yet been established. Although HDCYC has been shown to be an effective stimulus and is extensively used for PBPC mobilizaiton, the optimal dose has not been clearly defined until now. The results obtained for collection in our study compare favorably with those described in MM patients with a dose of 4 or 6 g/m 2 supported by HGF, 22, 26, 27 but there could be some justification in preferring the 7 g/m 2 dosage to a lower dosage.
First, a significantly greater number of hematopoietic PBPC could be harvested in comparison with patients who received a dose of 4 g/m 2 or less. Indeed, comparative studies have reported that an increase in the CYC dose resulted in an increase in the number of PBPC harvested, irrespective of whether HGF were used or not. 28, 29 In another study, patients treated with a lower dose of CYC had a less pronounced mobilization when compared with a high-dose CYC group. 30 Moreover, a significantly lower potentially malignant B cell content of autografts harvested after 7 g/m 2 is a further argument to prefer this dosage. 29 In this setting another advantage of the administration of HDCYC at 7 g/m 2 is a further potential reduction of the tumor mass. 31 However, an increased dose for both better mobilization and in vivo purging efficacy is associated with an increased toxicity. 28 In our study following HDCYC at 7 g/m 2 , toxic deaths related to infection were observed as recently reported by Goldsmidt et al 31 using the same dosage and by Jagannath et al 22 , despite the use of HGF in all studies. Thus, even if HGF could decrease the hematological toxicity of HDCYC, their use did not seem to change significantly this difference for the others. 29, 32 As we observed, other parameters also involved in PBPC collection efficiency such as duration of therapy before HDCYC are important for HDCYC tolerance. Indeed, in a more recent study reporting results of total therapy, no death was observed after HDCYC 6 g/m 2 in newly diagnosed MM patients. 33 At the present time it is difficult to reach a conclusion about the ideal dose of CYC for mobilization in MM patients. The dose-increased toxicity with toxic deaths observed could indicate that lower dosages such as 4 or 6 g/m 2 are preferable.
Even if the superiority of the combination of HGF and chemotherapy over HGF alone has been demonstrated for PBPC collection, 34 collection with HGF alone at the steady state also has to be considered. Results observed with G-CSF alone in newly diagnosed MM patients and more recently with a combination of G-CSF and stem cell factor (SCF) in heavily pretreated MM patients are encouraging, with collection of sufficient numbers of CD34 + cells and no significant toxicity. 35, 36 Another critical advantage is the ability to simplify the procedure and to treat these patients in a complete outpatient setting. 37 In 14% of our patients, the number of progenitor cells collected by leukaphereses was low, and both BM and PBPC had to be infused. This could be explained at least partially by the number and type of chemotherapy courses received before HDCYC. Indeed, as did others 26 we observed that more than 1 year of prior therapy and exposure to regimens containing stem cell-toxic drugs such as alkylating agents substantially reduces the ability to collect adequate PBPC even when HGF were used. 22 As previously described, 34 another important parameter was disease status which had a significant influence on the ability to mobilize a sufficient number of CD34 + cells but not CFU-GM cells.
HGF such as G-CSF or GM-CSF could increase the proportion of patients who have a successful collection. Results obtained in patients with MM 22 and other malignancies 38 showed that following HDCYC the administration of HGF enhanced the number of hematopoietic progenitors harvested. Preliminary results previously reported by our institution have indicated this tendency. 17 In the present study, the relatively insufficient number in each group and the heterogeneity of patients prevents definitive conclusions concerning the use of HGF. Nevertheless, multivariate analysis showed that this parameter is important as it was the only statistically important factor associated with collection of more than 25 × 10 4 CFU-GM cells/kg and 2 × 10 6 CD34 + cells/kg. However, in some of our patients, HGF administration was not necessarily followed by successful hematopoietic cell mobilization, indicating that the low releasing tendency of some MM patients could not be reversed by HGF. 30 Other factors such as the use of an alkylating agent are also important. However, more recently, the use of other HGF such as SCF in combination with G-CSF helped to mobilize hematopoietic progenitors with more efficiency in these patients. 36 In conclusion, HDCYC 7 g/m 2 is an efficient procedure for PBPC collection in high-risk MM patients. However, it is difficult to recommend it as there are toxic deaths which are less frequently observed using lower dosages. 28 Moreover, our results clearly indicate the need to collect MM patients early in the course of their disease, and if possible before the use of alkylating agents. This could lead to improving hematopoietic recovery post-ABPCT, as it is highly correlated with the number of hematopoietic progenitors infused. If high-dose therapy becomes the reference treatment for young patients with highrisk MM, as it seems it will, 6 it might be helpful to systematically collect these patients during the earlier phase of their disease.
